Study Seeking Those with Relapsing Neuromyelitis Optica (NMO)

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To Evaluate The Safety And Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)


The purpose of this study is to assess the efficacy, safety and tolerability of eculizumab treatment as compared with placebo in those with Relapsing Neuromyelitis Optica (NMO).

Eligibility criteria:

- Diagnosis of Neuromyelitis Optica (NMO)
- NMO-IgG seropositive either historical or at screening
- Historical Relapse of at least 2 relapses in the last 12 months or 3 relapses in the last 24 months, with at least 1 relapse in the 12 months

* Please contact study coordinator for more detailed inclusion/exclusion criteria

Contact Information

Stephanie Scarsberry